Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 – An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives

References

• Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Res. 2018;38:423–439. doi:10.1089/jir.2018.0089
   PubMed Web of Science ®Google Scholar
• Onuora S. Novel cytokine, IL-41, linked with PsA. Nat Rev Rheumatol. 2019;15:636.
   Google Scholar
• Justiz Vaillant AA, Qurie A. Interleukin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Maier E, Werner D, Duschl A, Bohle B, Horejs-Hoeck J. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J Immunol. 2014;193(2):645–654. doi:10.4049/jimmunol.1301836
   PubMed Web of Science ®Google Scholar
• Macedo RBV, Kakehasi AM, Melo de Andrade MV. IL33 in rheumatoid arthritis: potential contribution to pathogenesis. Rev Bras Reumatol. 2016;56:451–457. doi:10.1016/j.rbr.2016.01.006
   Google Scholar
• Interleukin 13. Available from: https://en.wikipedia.org/wiki/Interleukin_13#:~:text=IL%2D13%20is%20a%20cytokine,fibrosis%20and%20chitinase%20up%2Dregulation. Accessed February 10, 2022.
   Google Scholar
• Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19(5–6):347–356. doi:10.1016/j.cytogfr.2008.08.003
   PubMed Web of Science ®Google Scholar
• Furukawa S, Moriyama M, Miyake K, et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep. 2017;7:42413. doi:10.1038/srep42413
   PubMed Web of Science ®Google Scholar
• Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: roles in allergic inflammation and therapeutic perspectives. Front Immunol. 2019;10:364. doi:10.3389/fimmu.2019.00364
   PubMed Web of Science ®Google Scholar
• Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. 2018;2018:3858032. doi:10.1155/2018/3858032
   PubMed Web of Science ®Google Scholar
• Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677–90, quiz 691. doi:10.1067/mai.2003.1333
   PubMed Web of Science ®Google Scholar
• Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332:1284–1288. doi:10.1126/science.1204351
   PubMed Web of Science ®Google Scholar
• Ho I-C, Miaw S-C. Regulation of IL-4 expression in immunity and diseases. Adv Exp Med Biol. 2016;941:31–77. doi:10.1007/978-94-024-0921-5_3
   PubMed Web of Science ®Google Scholar
• Sempowski GD, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol. 1994;152:3606–3614.
   PubMed Web of Science ®Google Scholar
• Sommer M, Eismann U, Gerth J, Stein G. Interleukin 4 co-stimulates the PDGF-BB- and BFGF-mediated proliferation of mesangial cells and myofibroblasts. Nephron. 2002;92:868–880, discussion 880–882. doi:10.1159/000065451
   Web of Science ®Google Scholar
• Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertens. 2009;53(6):1041–1047. doi:10.1161/HYPERTENSIONAHA.108.123158
   PubMed Web of Science ®Google Scholar
• Yu Q, Horak K, Larson DF. Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertens. 2006;48(1):98–104. doi:10.1161/01.HYP.0000227247.27111.b2
   PubMed Web of Science ®Google Scholar
• Peng H, Yang X-P, Carretero OA, et al. Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice. Exp Physiol. 2011;96:756–764. doi:10.1113/expphysiol.2011.057612
   PubMed Web of Science ®Google Scholar
• Roselló-Lletí E, Rivera M, Bertomeu V, Cortés R, Jordán A, González-Molina A. Interleukin-4 and cardiac fibrosis in patients with heart failure. Rev Esp Cardiol. 2007;60:777–780. doi:10.1157/13108284
   PubMed Web of Science ®Google Scholar
• Catapano G, Pedone C, Nunziata E, Zizzo A, Passantino A, Incalzi RA. Nutrient intake and serum cytokine pattern in elderly people with heart failure. Eur J Heart Fail. 2008;10:428–434. doi:10.1016/j.ejheart.2008.02.016
   PubMed Web of Science ®Google Scholar
• Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res. 2012;95:77–85. doi:10.1093/cvr/cvs142
   PubMed Web of Science ®Google Scholar
• van Heuven-Nolsen D, De Kimpe SJ, Muis T, et al. Opposite role of interferon-gamma and interleukin-4 on the regulation of blood pressure in mice. Biochem Biophys Res Commun. 1999;254:816–820. doi:10.1006/bbrc.1998.8742
   PubMed Web of Science ®Google Scholar
• Lee YW, Kühn H, Kaiser S, Hennig B, Daugherty A, Toborek M. Interleukin 4 induces transcription of the 15-lipoxygenase I gene in human endothelial cells. J Lipid Res. 2001;42:783–791. doi:10.1016/S0022-2275(20)31641-2
   PubMed Web of Science ®Google Scholar
• Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J Immunol. 2010;185:5539–5548. doi:10.4049/jimmunol.0904021
   PubMed Web of Science ®Google Scholar
• Yamaji-Kegan K, Takimoto E, Zhang A, et al. Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306:L1090–1103. doi:10.1152/ajplung.00279.2013
   PubMed Web of Science ®Google Scholar
• Shintani Y, Ito T, Fields L, et al. IL-4 as a repurposed biological drug for myocardial infarction through augmentation of reparative cardiac macrophages: proof-of-concept data in mice. Sci Rep. 2017;7:6877. doi:10.1038/s41598-017-07328-z
   PubMed Web of Science ®Google Scholar
• Sicklinger F, Meyer IS, Li X, et al. Basophils balance healing after myocardial infarction via IL-4/IL-13. J Clin Invest. 2021;131:136778. doi:10.1172/JCI136778
   Web of Science ®Google Scholar
• Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248–250. doi:10.1038/362248a0
   PubMed Web of Science ®Google Scholar
• McKenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA. 1993;90:3735–3739. doi:10.1073/pnas.90.8.3735
   PubMed Web of Science ®Google Scholar
• Akaiwa M, Yu B, Umeshita-Suyama R, et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine. 2001;13:75–84. doi:10.1006/cyto.2000.0814
   PubMed Web of Science ®Google Scholar
• Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, Entman ML. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol. 2011;50:248–256. doi:10.1016/j.yjmcc.2010.10.019
   PubMed Web of Science ®Google Scholar
• Amir O, Spivak I, Lavi I, Rahat MA. Changes in the monocytic subsets CD14dimCD16+ and CD14++CD16− in chronic systolic heart failure patients. Mediators Inflamm. 2012;2012:616384. doi:10.1155/2012/616384
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Inoue K, Hara Y, et al. Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy. Eur J Heart Fail. 2005;7:689–695. doi:10.1016/j.ejheart.2004.09.011
   PubMed Web of Science ®Google Scholar
• Stanya KJ, Jacobi D, Liu S, et al. Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest. 2013;123:261–271. doi:10.1172/JCI64941
   PubMed Web of Science ®Google Scholar
• Hofmann U, Knorr S, Vogel B, et al. Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail. 2014;7:822–830. doi:10.1161/CIRCHEARTFAILURE.113.001020
   PubMed Web of Science ®Google Scholar
• Parisi V, Cabaro S, D’Esposito V, et al. Epicardial adipose tissue and IL-13 response to myocardial injury drives left ventricular remodeling after ST elevation myocardial infarction. Front Physiol. 2020;11:575181. doi:10.3389/fphys.2020.575181
   PubMed Web of Science ®Google Scholar
• Yuan S-M. Interleukin-13 in the pathogenesis of pulmonary artery hypertension. J Lab Med. 2019;43:5–11. doi:10.1515/labmed-2018-0323
   Web of Science ®Google Scholar
• Cihakova D, Barin JG, Afanasyev M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172:1195–1208. doi:10.2353/ajpath.2008.070207
   PubMed Web of Science ®Google Scholar
• Yang H, Chen Y, Gao C. Interleukin-13 reduces cardiac injury and prevents heart dysfunction in viral myocarditis via enhanced M2 macrophage polarization. Oncotarget. 2017;8:99495–99503. doi:10.18632/oncotarget.20111
   PubMedGoogle Scholar
• Rotter Sopasakis V, Sandstedt J, Johansson M, et al. Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions. Int J Cardiol. 2019;293:238–247. doi:10.1016/j.ijcard.2019.06.033
   PubMed Web of Science ®Google Scholar
• Vianello E, Marrocco-Trischitta Massimiliano M, Dozio E, et al. Correlational study on altered epicardial adipose tissue as a stratification risk factor for valve disease progression through IL-13 signaling. J Mol Cell Cardiol. 2019;132:210–218. doi:10.1016/j.yjmcc.2019.05.012
   PubMed Web of Science ®Google Scholar
• Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–760. doi:10.1038/ni1084
   PubMed Web of Science ®Google Scholar
• Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172:2225–2231. doi:10.4049/jimmunol.172.4.2225
   PubMed Web of Science ®Google Scholar
• Song H, Peng Y, Zhou B, et al. Associations between interleukin-31 gene polymorphisms and dilated cardiomyopathy in a Chinese population. Dis Markers. 2017;2017:4191365. doi:10.1155/2017/4191365
   PubMed Web of Science ®Google Scholar
• Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, Gp130, and its regulated expression in vivo. J Immunol. 1992;148:4066–4071.
   PubMed Web of Science ®Google Scholar
• Lafontant PJ, Burns AR, Donnachie E, Haudek SB, Smith CW, Entman ML. Oncostatin M differentially regulates CXC chemokines in mouse cardiac fibroblasts. Am J Physiol Cell Physiol. 2006;291:C18–26. doi:10.1152/ajpcell.00322.2005
   PubMed Web of Science ®Google Scholar
• Kunsleben N, Rüdrich U, Gehring M, Novak N, Kapp A, Raap U. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015;135:1908–1911. doi:10.1038/jid.2015.106
   PubMed Web of Science ®Google Scholar
• Cheung PF-Y, Wong C-K, Ho AW-Y, Hu S, Chen D-P, Lam CW-K. Activation of human eosinophils and epidermal keratinocytes by Th2 Cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22:453–467. doi:10.1093/intimm/dxq027
   PubMed Web of Science ®Google Scholar
• Tseng W-N, Lo M-H, Guo MM-H, Hsieh K-S, Chang W-C, Kuo H-C. IL-31 associated with coronary artery lesion formation in Kawasaki disease. PLoS One. 2014;9:e105195. doi:10.1371/journal.pone.0105195
   PubMed Web of Science ®Google Scholar
• Miller AM. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22. doi:10.1186/1476-9255-8-22
   Google Scholar
• Pascual-Reguant A, BayatSarmadi J, Baumann C, et al. TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine. Mucosal Immunol. 2017;10:1431–1442. doi:10.1038/mi.2017.5
   PubMed Web of Science ®Google Scholar
• Jha HC, Divya A, Prasad J, Mittal A. Plasma circulatory markers in male and female patients with coronary artery disease. Heart Lung J Crit Care. 2010;39:296–303. doi:10.1016/j.hrtlng.2009.10.005
   PubMed Web of Science ®Google Scholar
• Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014;9:e95055. doi:10.1371/journal.pone.0095055
   PubMed Web of Science ®Google Scholar
• Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 2011;30:825–830. doi:10.1007/s10067-011-1686-5
   PubMed Web of Science ®Google Scholar
• Komine M, Sato A, Adachi A, et al. Nuclear expression of IL-33 in epidermal keratinocyte is up-regulated in differentiated cells, while suppressed in proliferating cells. J Dermatol Sci. 2016;84:e43. doi:10.1016/j.jdermsci.2016.08.138
   Google Scholar
• Travers J, Rochman M, Wen T, Rothenberg ME. IL-33 is selectively expressed by esophageal basal layer epithelial cells during allergic inflammation. J Allergy Clin Immunol. 2016;137:AB228. doi:10.1016/j.jaci.2015.12.879
   Web of Science ®Google Scholar
• Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy J. 2002;32:1520–1526. doi:10.1046/j.1365-2745.2002.01494.x
   PubMed Web of Science ®Google Scholar
• Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475. doi:10.3389/fimmu.2017.00475
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–1549. doi:10.1172/JCI30634
   PubMed Web of Science ®Google Scholar
• Chen W-Y, Hong J, Gannon J, Kakkar R, Lee RT. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci USA. 2015;112:7249–7254. doi:10.1073/pnas.1424236112
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Sanada S, Okuda K, et al. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem Pharmacol. 2017;138:73–80. doi:10.1016/j.bcp.2017.04.022
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta Int J Clin Chem. 2015;443:57–70. doi:10.1016/j.cca.2014.09.021
   PubMed Web of Science ®Google Scholar
• Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K. The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects. J Hum Hypertens. 2014;28:432–437. doi:10.1038/jhh.2013.130
   PubMed Web of Science ®Google Scholar
• Ho JE, Larson MG, Ghorbani A, et al. Soluble ST2 predicts elevated SBP in the community. J Hypertens. 2013;31:1431–1436;discussion 1436. doi:10.1097/HJH.0b013e3283611bdf
   Web of Science ®Google Scholar
• Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study. Clin Chem. 2012;58:1673–1681. doi:10.1373/clinchem.2012.192153
   PubMed Web of Science ®Google Scholar
• Zheng Y-G, Yang T, He J-G, et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol. 2014;37:365–370. doi:10.1002/clc.22262
   PubMed Web of Science ®Google Scholar
• Agoston-Coldea L, Lupu S, Hicea S, Paradis A, Mocan T. Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med. 2014;8:95–106. doi:10.2217/bmm.13.116
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. 2010;160:721–728. doi:10.1016/j.ahj.2010.06.033
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Messalli G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol. 2013;168:1545–1547. doi:10.1016/j.ijcard.2012.12.031
   PubMed Web of Science ®Google Scholar
• Mohsen K. Serum levels of interleukin (IL)-33 in patients with ischemic heart disease. MOJ Immunol. 2018;6(2):29–32.
   Google Scholar
• McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell formation. J Immunol. 2010;185:1222–1229. doi:10.4049/jimmunol.1000520
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–691. doi:10.1161/CIRCHEARTFAILURE.109.873240
   PubMed Web of Science ®Google Scholar
• Ruisong M, Xiaorong H, Gangying H, et al. The protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38 MAPK signaling pathway. PLoS One. 2015;10:e0143064. doi:10.1371/journal.pone.0143064
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205:339–346. doi:10.1084/jem.20071868
   PubMed Web of Science ®Google Scholar
• Abston ED, Barin JG, Cihakova D, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail. 2012;5:366–375. doi:10.1161/CIRCHEARTFAILURE.111.963769
   PubMed Web of Science ®Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway–a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131:179–186. doi:10.1016/j.pharmthera.2011.02.005
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ionescu MA. Multiple autoimmune syndrome type 3- thyroiditis, vitiligo and alopecia areata. Acta Endocrinol Buchar. 2017;13:124–125. doi:10.4183/aeb.2017.124
   PubMed Web of Science ®Google Scholar
• Nwabudike LC, Tatu AL, Happle R, et al. Koebner’s sheep in wolf’s clothing: does the isotopic response exists as a distinct phenomenon? J Eur Acad Dermatol Venereol. 2018;32:e336–e337. doi:10.1111/jdv.14900
   PubMed Web of Science ®Google Scholar
• Tatu AL, Nwabudike LC. The treatment options of male genital lichen sclerosus et atrophicus. In: Proceedings of the 14th National Congress of Urogynecology and the National Conference of the Romanian Association for the Study of Pain; 2017:262–264.
   Google Scholar
• Niculet E, Chioncel V, Elisei AM, et al. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (review). Exp Ther Med. 2021;21:263. doi:10.3892/etm.2021.9693
   PubMed Web of Science ®Google Scholar
• Elisei A, Nwabudike LC, Buzia OD, Miulescu M, Tatu AL. Statins. A review on structural perspectives, adverse reactions and relations with non-melanoma skin cancer. Rev Chim. 2018;69:2557–2562.
   Web of Science ®Google Scholar
• Tatu AL. Umbilicated blue-black lesion on the lateral thorax. J Cutan Med Surg. 2017;21:252. doi:10.1177/1203475417694859
   PubMed Web of Science ®Google Scholar
• Hoon DS, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res. 1991;51:2002–2008.
   PubMed Web of Science ®Google Scholar
• Lee HL, Park MH, Song JK, et al. Tumor growth suppressive effect of IL-4 through P21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models. Oncotarget. 2016;7:23425–23438. doi:10.18632/oncotarget.8111
   PubMedGoogle Scholar
• Whitehead RP, Unger JM, Goodwin JW, et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a southwest oncology group study. J Immunother. 1998;21(6):440–446. doi:10.1097/00002371-199811000-00006
   PubMed Web of Science ®Google Scholar
• Chong ST, Tan KM, Kok CYL, et al. IL13RA2 is differentially regulated in papillary thyroid carcinoma vs follicular thyroid carcinoma. J Clin Endocrinol Metab. 2019;104:5573–5584. doi:10.1210/jc.2019-00040
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yoshimatsu Y, Tomizawa T, et al. Interleukin-13 receptor Α2 is a novel marker and potential therapeutic target for human melanoma. Sci Rep. 2019;9:1281. doi:10.1038/s41598-019-39018-3
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99–106. doi:10.1038/nm1332
   PubMed Web of Science ®Google Scholar
• Castellani ML, Felaco P, Galzio RJ, et al. IL-31 a Th2 cytokine involved in immunity and inflammation. Int J Immunopathol Pharmacol. 2010;23:709–713. doi:10.1177/039463201002300304
   PubMed Web of Science ®Google Scholar
• Bodoor K, Al-Qarqaz F, Heis LA, et al. IL-33/13 axis and IL-4/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis. Clin Cosmet Investig Dermatol. 2020;13:419–424. doi:10.2147/CCID.S257647
   PubMed Web of Science ®Google Scholar
• Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. doi:10.3389/fimmu.2018.00888
   PubMed Web of Science ®Google Scholar
• Bitton A, Avlas S, Reichman H, et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci Immunol. 2020;5:eaaw2938. doi:10.1126/sciimmunol.aaw2938
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54–62. doi:10.1111/all.13954
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–449. doi:10.1111/bjd.19574
   PubMed Web of Science ®Google Scholar
• TameezUd Din A, Malik I, Arshad D, TameezUd Din A. Dupilumab for atopic dermatitis: the silver bullet we have been searching for? Cureus. 2020;12:e7565. doi:10.7759/cureus.7565
   PubMed Web of Science ®Google Scholar
• Wozel G, Vitéz L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol Online J. 2006;12:6.
   PubMedGoogle Scholar
• Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145:572–582. doi:10.1016/j.jaci.2019.08.042
   PubMed Web of Science ®Google Scholar
• Lee YS, Han S-B, Ham HJ, et al. IL-32γ suppressed atopic dermatitis through inhibition of MiR-205 expression via inactivation of nuclear factor-kappa B. J Allergy Clin Immunol. 2020;146:156–168. doi:10.1016/j.jaci.2019.12.905
   PubMed Web of Science ®Google Scholar
• IL-31 drug succeeds for Prurigo Nodularis — less itching and twice as many lesions resolved with investigational agent. MedpageToday. Available from: https://www.medpagetoday.com/dermatology/generaldermatology/84974. Accessed July 10, 2022.
   Google Scholar
• Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med. 2021;8:638325. doi:10.3389/fmed.2021.638325
   PubMed Web of Science ®Google Scholar
• Asano Y. Recent advances in animal models of systemic sclerosis. J Dermatol. 2016;43:19–28. doi:10.1111/1346-8138.13185
   PubMed Web of Science ®Google Scholar
• Guggino G, Lo Pizzo M, Di Liberto D, et al. Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients. Clin Exp Immunol. 2017;190:208–216. doi:10.1111/cei.13009
   PubMed Web of Science ®Google Scholar
• Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med. 2015;15(6):s58–63. doi:10.7861/clinmedicine.15-6-s58
   PubMedGoogle Scholar
• Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, et al. Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. BioMed Res Int. 2019;2019:4569826. doi:10.1155/2019/4569826
   PubMed Web of Science ®Google Scholar
• Asano Y. Systemic sclerosis. J Dermatol. 2018;45:128–138. doi:10.1111/1346-8138.14153
   PubMed Web of Science ®Google Scholar
• Altorok N, Wang Y, Kahaleh B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol. 2014;26:615–620. doi:10.1097/BOR.0000000000000112
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Steen V, Nash P, Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatol Oxf. 2009;48(3):iii8–13. doi:10.1093/rheumatology/ken482
   PubMed Web of Science ®Google Scholar
• Liakouli V, Elies J, El-Sherbiny YM, et al. Scleroderma fibroblasts suppress angiogenesis via tgf-β/caveolin-1 dependent secretion of pigment epithelium-derived factor. Ann Rheum Dis. 2018;77:431–440. doi:10.1136/annrheumdis-2017-212120
   PubMed Web of Science ®Google Scholar
• Atamas SP, White B. Interleukin 4 in systemic sclerosis: not just an increase. Clin Diagn Lab Immunol. 1999;6:658–659. doi:10.1128/CDLI.6.5.658-659.1999
   PubMedGoogle Scholar
• Gasparini G, Cozzani E, Parodi A. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine. 2020;125:154799. doi:10.1016/j.cyto.2019.154799
   PubMed Web of Science ®Google Scholar
• Cascio S, Medsger TA, Hawse WF, et al. 14-3-3z sequesters cytosolic T-Bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma. J Allergy Clin Immunol. 2018;142:109–119.e6. doi:10.1016/j.jaci.2017.10.029
   PubMed Web of Science ®Google Scholar
• Manetti M, Pratesi S, Romano E, et al. Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. Ann Rheum Dis. 2019;78:575–577. doi:10.1136/annrheumdis-2018-214240
   PubMed Web of Science ®Google Scholar
• Yamashita T, Lakota K, Taniguchi T, et al. An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. Sci Rep. 2018;8:11843. doi:10.1038/s41598-018-29901-w
   PubMed Web of Science ®Google Scholar
• Yaseen B, Lopez H, Taki Z, et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatol Oxf. 2020;59:2625–2636. doi:10.1093/rheumatology/keaa195
   PubMed Web of Science ®Google Scholar
• Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12:5947. doi:10.1038/s41467-021-26099-w
   PubMed Web of Science ®Google Scholar
• Wagner A, Köhm M, Nordin A, Svenungsson E, Pfeilschifter JM, Radeke HH. Increased serum levels of the IL-33 neutralizing SST2 in limited cutaneous systemic sclerosis. Scand J Immunol. 2015;82:269–274. doi:10.1111/sji.12317
   PubMed Web of Science ®Google Scholar
• Murdaca G, Greco M, Tonacci A, et al. IL-33/IL-31 axis in immune-mediated and allergic diseases. Int J Mol Sci. 2019;20:5856. doi:10.3390/ijms20235856
   PubMed Web of Science ®Google Scholar
• Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatol Oxf. 2018;57:vi4–vi9. doi:10.1093/rheumatology/key001
   PubMed Web of Science ®Google Scholar
• Dong C, Fu T, Ji J, Li Z, Gu Z. The role of interleukin-4 in rheumatic diseases. Clin Exp Pharmacol Physiol. 2018;45:747–754. doi:10.1111/1440-1681.12946
   PubMed Web of Science ®Google Scholar
• Lin S, Qiu M, Chen J. IL-4 modulates macrophage polarization in ankylosing spondylitis. Cell Physiol Biochem. 2015;35:2213–2222. doi:10.1159/000374026
   PubMedGoogle Scholar
• Wang J, Zhao Q, Wang G, et al. Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis. Cytokine. 2016;81:10–14. doi:10.1016/j.cyto.2016.01.012
   PubMed Web of Science ®Google Scholar
• Li X, Lin T, Qi C, et al. Elevated serum level of IL-33 and SST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med. 2013;61:848–851. doi:10.2310/JIM.0b013e31828deed2
   PubMed Web of Science ®Google Scholar
• Talabot-Ayer D, McKee T, Gindre P, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79:32–37. doi:10.1016/j.jbspin.2011.02.011
   PubMed Web of Science ®Google Scholar
• Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M. Systemic lupus erythematosus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Singh RR. IL-4 and many roads to lupus-like autoimmunity. Clin Immunol. 2003;108:73–79. doi:10.1016/S1521-6616(03)00145-1
   PubMed Web of Science ®Google Scholar
• Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol. 1997;158:1466–1472.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Morimoto S, Kaneko H, et al. Decreased IL-4 producing CD4+ T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression. Autoimmunity. 2002;35(6):381–387. doi:10.1080/0891693021000008535
   PubMed Web of Science ®Google Scholar
• Reséndiz-Mora A, Wong-Baeza C, Nevárez-Lechuga I, et al. Interleukin 4 deficiency limits the development of a lupus-like disease in mice triggered by phospholipids in a non-bilayer arrangement. Scand J Immunol. 2021;93(3):e13002. doi:10.1111/sji.13002
   PubMed Web of Science ®Google Scholar
• Morimoto S, Tokano Y, Kaneko H, Nozawa K, Amano H, Hashimoto H. The increased interleukin-13 in patients with systemic lupus erythematosus: relations to other Th1-, Th2-related cytokines and clinical findings. Autoimmunity. 2001;34:19–25. doi:10.3109/08916930108994122
   PubMed Web of Science ®Google Scholar
• Wang R, Lu Y-L, Huang H-T, et al. Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus. Cytokine. 2018;104:92–97. doi:10.1016/j.cyto.2017.09.034
   PubMed Web of Science ®Google Scholar
• Huang H-T, Chen J-M, Guo J, Lan Y, Wei Y-S. The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int. 2016;36:799–805. doi:10.1007/s00296-016-3422-6
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med. 2011;11(2):75–80. doi:10.1007/s10238-010-0115-4
   PubMed Web of Science ®Google Scholar
• Moreau A, Nicaise C, Awada A, Soyfoo MS. Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis. Clin Exp Rheumatol. 2021;2021:34128798.
   Google Scholar
• Mohd Jaya FN, Liu Z, Chan GC. Early treatment of interleukin-33 can attenuate lupus development in young NZB/W F1 mice. Cells. 2020;9(11):2448. doi:10.3390/cells9112448
   PubMed Web of Science ®Google Scholar
• Firestein G, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196. doi:10.1016/j.immuni.2017.02.006
   PubMed Web of Science ®Google Scholar
• Finnegan A, Grusby MJ, Kaplan CD, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through stat-dependent mechanisms. J Immunol Baltim. 2002;169:3345–3352. doi:10.4049/jimmunol.169.6.3345
   PubMed Web of Science ®Google Scholar
• Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (Aggrecan)-induced arthritis in BALB/c mice Is a Th1-type disease regulated by Th2 cytokines. J Immunol Baltim. 1999;163:5383–5390.
   PubMed Web of Science ®Google Scholar
• Martin-Martin LS, Giovannangeli F, Bizzi E, et al. An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. Drug Des Devel Ther. 2017;11:985–994. doi:10.2147/DDDT.S118298
   PubMed Web of Science ®Google Scholar
• Shen H, Xia L, Lu J. Interleukin-4 in rheumatoid arthritis patients with interstitial lung disease: a pilot study. Indian J Med Res. 2013;138:919–921.
   PubMed Web of Science ®Google Scholar
• Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. J Rheumatol. 2002;29:454–461.
   PubMed Web of Science ®Google Scholar
• Siloşi I, Boldeanu MV, Cojocaru M, et al.. The relationship of cytokines IL-13 and IL-17 with autoantibodies profile in early rheumatoid arthritis. J Immunol Res. 2016;3109135. doi:10.1155/2016/3109135
   PubMed Web of Science ®Google Scholar
• Duan L, Chen J, Gong F, Shi G. The role of IL-33 in rheumatic diseases. Clin Dev Immunol. 2013;924363. doi:10.1155/2013/924363
   PubMedGoogle Scholar
• Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol Baltim. 2012;189:4213–4219. doi:10.4049/jimmunol.1202246
   PubMed Web of Science ®Google Scholar
• King E, O’Brien JT, Donaghy P, et al. Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89:339–345. doi:10.1136/jnnp-2017-317134
   PubMed Web of Science ®Google Scholar
• Derecki NC, Cardani AN, Yang CH, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med. 2010;207:1067–1080. doi:10.1084/jem.20091419
   PubMed Web of Science ®Google Scholar
• Dionisio-Santos DA, Behrouzi A, Olschowka JA, O’Banion MK. Evaluating the effect of interleukin-4 in the 3xTg mouse model of Alzheimer’s disease. Front Neurosci. 2020;14:441. doi:10.3389/fnins.2020.00441
   PubMed Web of Science ®Google Scholar
• Brombacher TM, Nono JK, De Gouveia KS, et al. IL-13-mediated regulation of learning and memory. J Immunol Baltim. 2017;198:2681–2688. doi:10.4049/jimmunol.1601546
   PubMed Web of Science ®Google Scholar
• Mori S, Maher P, Conti B. Neuroimmunology of the interleukins 13 and 4. Brain Sci. 2016;6:E18. doi:10.3390/brainsci6020018
   PubMed Web of Science ®Google Scholar
• Brombacher TM, Berkiks I, Pillay S, Scibiorek M, Moses BO, Brombacher F. IL-4R alpha deficiency influences hippocampal-BDNF signaling pathway to impair reference memory. Sci Rep. 2020;10:16506. doi:10.1038/s41598-020-73574-3
   PubMed Web of Science ®Google Scholar
• Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer’s disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014;40:297–308. doi:10.3233/JAD-132081
   PubMed Web of Science ®Google Scholar
• Fairlie-Clarke K, Barbour M, Wilson C, Hridi SU, Allan D, Jiang H-R. Expression and function of IL-33/ST2 axis in the central nervous system under normal and diseased conditions. Front Immunol. 2018;9:2596. doi:10.3389/fimmu.2018.02596
   PubMed Web of Science ®Google Scholar
• Saresella M, Marventano I, Piancone F, et al. IL-33 and its decoy SST2 in patients with Alzheimer’s disease and mild cognitive impairment. J Neuroinflammation. 2020;17:174. doi:10.1186/s12974-020-01806-4
   PubMed Web of Science ®Google Scholar
• Sun Y, Wen Y, Wang L, et al. Therapeutic opportunities of interleukin-33 in the central nervous system. Front Immunol. 2021;12:654626. doi:10.3389/fimmu.2021.654626
   PubMed Web of Science ®Google Scholar
• Du L-X, Wang Y-Q, Hua G-Q, Mi W-L. IL-33/ST2 pathway as a rational therapeutic target for CNS diseases. Neuroscience. 2018;369:222–230. doi:10.1016/j.neuroscience.2017.11.028
   PubMed Web of Science ®Google Scholar
• Abd RachmanIsnadi MF, Chin VK, Abd Majid R, et al. Critical roles of IL-33/ST2 pathway in neurological disorders. Mediators Inflamm. 2018;2018:5346413. doi:10.1155/2018/5346413
   PubMed Web of Science ®Google Scholar
• Reverchon F, de Concini V, Larrigaldie V, et al. Hippocampal interleukin-33 mediates neuroinflammation-induced cognitive impairments. J Neuroinflammation. 2020;17:268. doi:10.1186/s12974-020-01939-6
   PubMed Web of Science ®Google Scholar
• Yan Z, Yang W, Wei H, et al. Dysregulation of the adaptive immune system in patients with early-stage Parkinson disease. Neurol Neuroimmunol Neuroinflammation. 2021;8:e1036. doi:10.1212/NXI.0000000000001036
   PubMed Web of Science ®Google Scholar
• Morrison BE, Marcondes MCG, Nomura DK, et al. Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol Baltim. 2012;189:5498–5502. doi:10.4049/jimmunol.1102150
   PubMed Web of Science ®Google Scholar
• Bok E, Cho EJ, Chung ES, Shin W-H, Jin BK. Interleukin-4 contributes to degeneration of dopamine neurons in the lipopolysaccharide-treated substantia nigra in vivo. Exp Neurobiol. 2018;27:309–319. doi:10.5607/en.2018.27.4.309
   PubMed Web of Science ®Google Scholar
• Mori S, Sugama S, Nguyen W, et al. Lack of interleukin-13 receptor Α1 delays the loss of dopaminergic neurons during chronic stress. J Neuroinflammation. 2017;14:88. doi:10.1186/s12974-017-0862-1
   PubMed Web of Science ®Google Scholar
• Aguirre CA, Concetta Morale M, Peng Q, et al. Two single nucleotide polymorphisms in IL13 and IL13RA1 from individuals with idiopathic Parkinson’s disease increase cellular susceptibility to oxidative stress. Brain Behav Immun. 2020;88:920–924. doi:10.1016/j.bbi.2020.04.007
   PubMed Web of Science ®Google Scholar
• Rossi C, Cusimano M, Zambito M, et al. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:250. doi:10.1038/s41419-018-0288-4
   PubMed Web of Science ®Google Scholar
• Korhonen P, Pollari E, Kanninen KM, et al. Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. IBRO Rep. 2019;6:74–86. doi:10.1016/j.ibror.2019.01.005
   PubMedGoogle Scholar
• Falcone M, Rajan AJ, Bloom BR, Brosnan CF. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol Baltim. 1998;160:4822–4830.
   PubMed Web of Science ®Google Scholar
• Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci. 2007;27:10714–10721. doi:10.1523/JNEUROSCI.1922-07.2007
   PubMed Web of Science ®Google Scholar
• Ghezzi L, Cantoni C, Cignarella F, et al. T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients. Mult Scler. 2020;26:1172–1186. doi:10.1177/1352458519852092
   PubMed Web of Science ®Google Scholar
• Allan D, Fairlie-Clarke KJ, Elliott C, et al. Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol Commun. 2016;4:75. doi:10.1186/s40478-016-0344-1
   PubMed Web of Science ®Google Scholar
• Ygberg S, Fowler Å, Wickström R. Age-related changes in the inflammatory responses to viral infections in the central nervous system during childhood. Pediatr Res. 2022;91(1):204–208. doi:10.1038/s41390-021-01423-8
   PubMed Web of Science ®Google Scholar
• Silva HM, Vinaud MC, de Lino RS. Experimental neurocysticercosis: absence of IL-4 induces lower encephalitis. Arq Neuropsiquiatr. 2017;75:96–102. doi:10.1590/0004-282x20160194
   PubMed Web of Science ®Google Scholar
• Peng H, Sun R, Zhang Q, et al. Interleukin 33 mediates type 2 immunity and inflammation in the central nervous system of mice infected with angiostrongylus cantonensis. J Infect Dis. 2013;207:860–869. doi:10.1093/infdis/jis682
   PubMed Web of Science ®Google Scholar
• Palomo J, Reverchon F, Piotet J, et al. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development. Eur J Immunol. 2015;45:1354–1365. doi:10.1002/eji.201445206
   PubMed Web of Science ®Google Scholar
• Franca RFO, Costa RS, Silva JR, et al. IL-33 signaling is essential to attenuate viral-induced encephalitis development by downregulating INOS expression in the central nervous system. J Neuroinflammation. 2016;13:159. doi:10.1186/s12974-016-0628-1
   PubMed Web of Science ®Google Scholar
• Reverchon F, Mortaud S, Sivoyon M, et al. IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS Pathog. 2017;13:e1006322.
   PubMed Web of Science ®Google Scholar
• Kolosowska N, Keuters MH, Wojciechowski S, et al. Peripheral administration of IL-13 induces anti-inflammatory microglial/macrophage responses and provides neuroprotection in ischemic stroke. Neurotherapeutics. 2019;16:1304–1319. doi:10.1007/s13311-019-00761-0
   PubMed Web of Science ®Google Scholar
• Perego C, Fumagalli S, Miteva K, Kallikourdis M, De Simoni M-G. Combined genetic deletion of IL (Interleukin)-4, IL-5, IL-9, and IL-13 does not affect ischemic brain injury in mice. Stroke. 2019;50:2207–2215. doi:10.1161/STROKEAHA.119.025196
   PubMed Web of Science ®Google Scholar
• Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013;4:18. doi:10.3389/fneur.2013.00018
   PubMed Web of Science ®Google Scholar
• Pu H, Ma C, Zhao Y, et al. Intranasal delivery of interleukin-4 attenuates chronic cognitive deficits via beneficial microglial responses in experimental traumatic brain injury. J Cereb Blood Flow Metab. 2021;41(11):2870–2886. doi:10.1177/0271678X211028680
   PubMed Web of Science ®Google Scholar
• Miao W, Zhao Y, Huang Y, et al. IL-13 ameliorates neuroinflammation and promotes functional recovery after traumatic brain injury. J Immunol Baltim. 2020;204:1486–1498. doi:10.4049/jimmunol.1900909
   PubMed Web of Science ®Google Scholar
• Miao Y, Zhang Z-X, Feng X, Sun W-M. IL-33 as a novel serum prognostic marker of intracerebral hemorrhage. Oxid Med Cell Longev. 2021;2021:5597790. doi:10.1155/2021/5597790
   PubMed Web of Science ®Google Scholar
• de Toscano ECB, Lessa JMK, de Oliveira GN, et al. Peripheral levels of SST2 are increased in patients with temporal lobe epilepsy: additional evidence of low-grade inflammation. Epilepsy Behav. 2020;112:107351. doi:10.1016/j.yebeh.2020.107351
   PubMed Web of Science ®Google Scholar
• Gao Y, Luo C, Yao Y, et al. IL-33 alleviated brain damage via anti-apoptosis, endoplasmic reticulum stress, and inflammation after epilepsy. Front Neurosci. 2020;14:898. doi:10.3389/fnins.2020.00898
   PubMed Web of Science ®Google Scholar
• Ethemoglu O, Calık M, Koyuncu I, et al. Interleukin-33 and oxidative stress in epilepsy patients. Epilepsy Res. 2021;176:106738. doi:10.1016/j.eplepsyres.2021.106738
   PubMed Web of Science ®Google Scholar
• Takamori A, Nambu A, Sato K, et al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Sci Rep. 2018;8:6639. doi:10.1038/s41598-018-25094-4
   PubMed Web of Science ®Google Scholar
• Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med. 2021;8:639097. doi:10.3389/fmed.2021.639097
   Web of Science ®Google Scholar
• De Boeck A, Ahn BY, D’Mello C, et al. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat Commun. 2020;11:4997. doi:10.1038/s41467-020-18569-4
   PubMed Web of Science ®Google Scholar
• Lin L, Li Y, Liu M, Li Q, Liu Q, Li R. The interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation. Aging. 2020;12(2):1685–1703. doi:10.18632/aging.102707
   PubMedGoogle Scholar
• Thürmann L, Herberth G, Rolle-Kampczyk U, et al. Elevated gestational IL-13 during fetal development is associated with hyperactivity and inattention in eight-year-old children. Front Immunol. 2019;10:1658. doi:10.3389/fimmu.2019.01658
   PubMed Web of Science ®Google Scholar
• Dohi E, Choi EY, Rose IVL, et al. Behavioral changes in mice lacking interleukin-33. eNeuro. 2017;4(6):ENEURO.0147–17.2017. doi:10.1523/ENEURO.0147-17.2017
   PubMed Web of Science ®Google Scholar
• Vainchtein ID, Chin G, Cho FS, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science. 2018;359:1269–1273. doi:10.1126/science.aal3589
   PubMed Web of Science ®Google Scholar
• Pandolfo G, Genovese G, Casciaro M, et al. IL-33 in mental disorders. Medicina. 2021;57(4):315. doi:10.3390/medicina57040315
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar